User:Mr. Ibrahem/Melphalan flufenamide

Melphalan flufenamide, sold under the brand name Pepaxto, is an medication used to treat multiple myeloma. It is used when other treatments have failed, together with dexamethasone. It is given by gradual injection into a vein.

Common side effects include low platelets, low neutrophils, low red blood cells, nausea, diarrhea, and fever. Severe side effects include pneumonia. Use in pregnancy may harm the baby. It is an alkylating agent that interferes with the normal repair of DNA.

Melphalan flufenamide was approved for medical use in the United States in February of 2021 and Europe in 2022. The manufacturer withdrew the medication in October of 2021 due to concerns of worsened outcomes; however, it is thinking of reversing this decision. It is not approved in the United Kingdom as of 2022.